JPRN-UMIN000006071已完成2 期
Allogeneic hematopoietic stem cell transplantation for aplastic anemia using low-dose anti-thymocyte globulin - HSCT for AA using low-dose ATG
Kanto Study Group for Cell Therapy0 个研究点目标入组 28 人开始时间: 2011年8月31日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 65years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria 1. Patients with poorly controlled DM 2. Patients with poorly controlled hypertension 3. Patients with poorly controlled active infection 4. Patients with chromosome 7 abnormality 5. Patients with coexistence of malignancy 6. Patients who are pregnant or nursing 7. Patients with serious mental disorder 8. Patients with HBs antigen or HBe antigen positive 9. Patients with HIV antibody positive 10. Patients who are allergic to drugs used in conditioning regimen 11. Patients who had undergone allogeneic HSCT
研究者
相似试验
已完成
不适用
Allogeneic hematopoietic stem cell transplantation for elderly patientsJPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50
已完成
不适用
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)JPRN-UMIN000026028Osaka City University33
招募中
2 期
Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children's Hospital phase II studyAcute leukemia, malignant lymphoma, and solid tumorJPRN-UMIN000027010Ibaraki Children's Hospital30
进行中(未招募)
1 期
Stem cells transplant from matched donor in patients with chronic myeloid leukemia who do not improve with TKI therapyChronic Myeloid LeukemiaMedDRA version: 18.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-003126-40-ITIVERSITà DEGLI STUDI MILANO BICOCCA20
已完成
不适用
Allogeneic hematopoietic stem cell transpalntation using Thymoglobulin for patients with T-cell malignancyT-cell malignancyJPRN-UMIN000015736ational Cancer Center Hospital15
